Table 2. GSTP1 allele frequencies and BC HR in BRCA1 and BRCA2 carriers (adjusted for origin, Ashkenazi vs non-Ashkenazi)a.
| BRCA1 (n=228) | BRCA2 (n=90) | |||||
|---|---|---|---|---|---|---|
| GSTP1 | BC− (n=78) no. (%) | BC+ (n=150) no. (%) | Breast cancer HR (95% CI, P) | BC− (n=29) no. (%) | BC+ (n=61) no. (%) | Breast cancer HR (95% CI, P) |
| Ile/Ile | 53 (67.9) | 86 (57.3) | 1 | 22 (75.9) | 35 (57.4) | 1 |
| Age at BC | 40.5 years | 46.6 years | ||||
| Ile/Val | 22 (28.2) | 54 (36) | 1.22 (0.87–1.72, P=0.24) | 7 (24.1) | 20 (32.8) | 1.50 (0.86–2.59, P=0.15) |
| Age at BC | 42.6 years | 42.6 years | ||||
| Val/Val | 3 (3.9) | 10 (6.7) | 1.38 (0.71–2.70, P=0.15) | 0 | 6 (9.8) | 3.20 (1.26–8.09, P=0.01) |
| Age at BC | 40.1 years | 41.2 years | ||||
BC−, no BC; BC+, with BC; CI, confidence interval; HI, hazard ratio.
aCompound heterozygotes were excluded from these analyses.